Zenas BioPharma (ZBIO), a clinical-stage immunology specialist, continues to attract attention after a year in which the stock’s total return is reported at 93.28%, contrasting with a year-to-date decline of 46.67%.

At the latest share price of $18.40, Zenas BioPharma’s recent 7 day and 90 day share price returns show declines, yet its 1 year total shareholder return of 93.28% still points to earlier gains, indicating that momentum has faded following a strong prior period.

If you are looking for other healthcare and biotech opportunities that use artificial intelligence, it could be a good time to scan the 37 healthcare AI stocks.

With Zenas BioPharma now valued at about US$1.17b and trading at US$18.40, the key question is whether recent weakness leaves the stock undervalued or if the market is already pricing in future growth.

Price to Book of 3.5x: Is It Justified?

On a P/B of 3.5x, Zenas BioPharma trades above the wider US Biotechs industry average of 2.6x, while still sitting below its closer peer group on 4.1x.

P/B compares the company’s market value to its book value, which is particularly relevant here because Zenas BioPharma currently reports no revenue and is loss making, with a reported net loss of $425.151m and negative return on equity of 126.6% over the past year.

Given that analysts forecast revenue to grow at 56.03% per year from a very low base of less than $1m, a higher than industry P/B suggests the market is willing to pay more for each dollar of net assets, while still pricing the stock at a lower level than peers with an average P/B of 4.1x.

Compared with the broader US Biotechs industry, the premium P/B multiple implies stronger expectations about Zenas BioPharma’s future revenue profile than the sector average. However, the absence of a fair ratio estimate means there is no regression based anchor for where the P/B multiple could settle over time, leaving investors to weigh the 3.5x figure directly against the 2.6x industry and 4.1x peer benchmarks.

Result: Price-to-book of 3.5x (OVERVALUED).

However, recent share price weakness and the company’s current losses of US$425.151m could quickly challenge the case for paying a premium 3.5x P/B.

Next Steps

After weighing both the premium valuation and the recent share price weakness, it makes sense to act promptly, review the full picture, and form your own view using the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If Zenas BioPharma has your attention, do not stop here. Use the tools available to widen your watchlist and uncover ideas you might otherwise miss.

• Spot potential mispricings early by scanning 46 high quality undervalued stocks that combine solid fundamentals with room for a rerating.
• Prioritise resilience by checking 62 resilient stocks with low risk scores that score well on financial health and business stability.
• Get ahead of the crowd by reviewing the screener containing 22 high quality undiscovered gems that rarely show up on typical stock lists.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.